Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective
GLP1 receptor agonists (GLP1-RAs) are drugs that mimic the effects of the incretin hormone GLP1 and were initially introduced in medicine for the treatment of diabetes in 2005 and for obesity in 2014. Over time, data from secondary and exploratory objectives of large randomized controlled-trials sug...
- Autores:
-
Rico-Fontalvo, Jorge
Reina, Maricely
Soler, María José
Unigarro-Palacios, Mario
Castañeda González, Juan Pablo
Jiménez Quintero, Javier
Raad Sarabia, Maria Isabel
Proenca de Moraes, Thyago
Daza-Arnedo, Rodrigo
- Tipo de recurso:
- Fecha de publicación:
- 2024
- Institución:
- Universidad Simón Bolívar
- Repositorio:
- Repositorio Digital USB
- Idioma:
- spa
- OAI Identifier:
- oai:bonga.unisimon.edu.co:20.500.12442/15936
- Acceso en línea:
- https://hdl.handle.net/20.500.12442/15936
https://doi.org/10.1590/2175-8239-JBN-2024-0101en
https://www.bjnephrology.org/en/article/kidney-effects-of-glucagon-like-peptide-1-glp1-from-molecular-foundations-to-a-pharmacophysiological-perspective/
- Palabra clave:
- Albuminuria
Diabetes
Incretins
Obesity
Kidney disease
Albuminúria
Diabetes
Incretinas
Obesidade
Doença Renal
- Rights
- openAccess
- License
- Attribution-NonCommercial-NoDerivs 3.0 United States